威斯康星大学治疗犬淋巴肉瘤的2年方案的重新评估。

Reevaluation of the University of Wisconsin 2-year protocol for treating canine lymphosarcoma.

作者信息

Kaiser Claire Inderbinen, Fidel Janean L, Roos Malgorzata, Kaser-Hotz Barbara

机构信息

Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington 99164-6610, USA.

出版信息

J Am Anim Hosp Assoc. 2007 Mar-Apr;43(2):85-92. doi: 10.5326/0430085.

DOI:10.5326/0430085

PMID:17339285

Abstract

This retrospective study investigated a population of 96 dogs with newly diagnosed malignant lymphosarcoma that were treated with the commonly used University of Wisconsin-Madison (UW-M) chemotherapy protocol. Pretreatment characteristics were analyzed to determine prognostic factors. Dogs with higher World Health Organization (WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher risk of relapse (P=0.018 and P=0.016, respectively). Dose reduction, treatment delays, and prior therapy with cortico-steroids were not associated with clinical outcome. First remission duration of 270 days was similar to historically reported data. Overall survival time of 218 days was much shorter than historical data.

摘要

这项回顾性研究调查了96只新诊断为恶性淋巴瘤的犬，这些犬接受了常用的威斯康星大学麦迪逊分校（UW-M）化疗方案治疗。分析预处理特征以确定预后因素。世界卫生组织（WHO）分期较高（包括IV期）的犬和患有高钙血症的犬复发风险显著更高（分别为P = 0.018和P = 0.016）。剂量减少、治疗延迟和先前使用皮质类固醇治疗与临床结果无关。270天的首次缓解期与历史报道数据相似。218天的总生存时间比历史数据短得多。